Greenwich LifeSciences, Inc.
- Open
- 15.62
- Day high
- 17.66
- Day low
- 15.61
- Prev close
- 15.55
- Volume
- 198K
- Mkt cap
- $242M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 45.8
- P/S
- —
- Yield
- —
- Per share
- —
- ▲Insiders net buying $97K over the last 3 months (5 open-market buys, 0 sales)
- 🏛Institutions accumulating (13F)
Greenwich LifeSciences, Inc. (GLSI) is a Healthcare company listed on NASDAQ. The stock is up 21% over the past year. Over the trailing 3 months, insiders filed 5 open-market buys and 0 sales (SEC Form 4).
Greenwich LifeSciences, Inc. (GLSI) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
GLSI earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 11, 2026 | $-0.33 | $-0.27 | +18.2% | — | — |
| Jun 3, 2026 | $-0.33 | $-0.39 | -18.2% | — | — |
| Nov 14, 2025 | $-0.30 | $-0.30 | +0.0% | — | — |
| Aug 14, 2025 | $-0.24 | $-0.30 | -25.0% | — | — |
| May 20, 2025 | $-0.24 | $-0.25 | -4.2% | — | — |
| Nov 14, 2024 | $-0.21 | $-0.20 | +4.8% | — | — |
| Aug 14, 2024 | $-0.20 | $-0.20 | +0.0% | — | — |
| May 20, 2024 | $-0.20 | $-0.19 | +5.0% | — | — |
| Oct 19, 2023 | $-0.22 | $-0.19 | +13.6% | — | — |
| Aug 21, 2023 | $-0.23 | $-0.13 | +43.5% | — | — |
| May 22, 2023 | $-0.23 | $-0.17 | +26.1% | — | — |
| Mar 31, 2023 | $-0.18 | $-0.22 | -22.2% | — | — |
GLSI insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 30, 2026 | Patel Snehaldirector, 10 percent owner, officer: CEO and CFO | Buy | 1,500 | $13.59 |
| Jul 30, 2026 | Patel Snehaldirector, 10 percent owner, officer: CEO and CFO | Buy | 700 | $13.10 |
| Jul 29, 2026 | Patel Snehaldirector, 10 percent owner, officer: CEO and CFO | Buy | 1,500 | $13.62 |
| Jul 27, 2026 | Patel Snehaldirector, 10 percent owner, officer: CEO and CFO | Buy | 2,500 | $13.14 |
| Jul 27, 2026 | Patel Snehaldirector, 10 percent owner, officer: CEO and CFO | Buy | 1,100 | $12.88 |
| Jan 15, 2026 | Patel Snehaldirector, 10 percent owner, officer: CEO and CFO | Buy | 1,800 | $29.83 |
| Jan 14, 2026 | Patel Snehaldirector, 10 percent owner, officer: CEO and CFO | Buy | 2,900 | $27.54 |
| Jan 5, 2026 | Patel Snehaldirector, 10 percent owner, officer: CEO and CFO | Buy | 4,300 | $21.36 |
| Jan 2, 2026 | Patel Snehaldirector, 10 percent owner, officer: CEO and CFO | Buy | 2,900 | $21.73 |
| Dec 19, 2025 | Patel Snehaldirector, 10 percent owner, officer: CEO and CFO | Buy | 4,100 | $12.62 |
| Nov 28, 2025 | Patel Snehaldirector, 10 percent owner, officer: CEO and CFO | Buy | 4,600 | $8.37 |
| Nov 17, 2025 | Patel Snehaldirector, 10 percent owner, officer: CEO and CFO | Grant | 100,000 | $8.20 |
| Nov 12, 2025 | Patel Snehaldirector, 10 percent owner, officer: CEO and CFO | Buy | 10,600 | $8.43 |
| Nov 4, 2025 | Patel Snehaldirector, 10 percent owner, officer: CEO and CFO | Buy | 2,300 | $9.26 |
| Apr 29, 2025 | Patel Snehaldirector, 10 percent owner, officer: CEO and CFO | Buy | 3,600 | $9.88 |
Source: GLSI SEC Form 4 filings, latest Jul 30, 2026. For informational purposes only — not investment advice.
See the full GLSI insider & 13F page →Greenwich LifeSciences, Inc. company profile
Overview
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in Stafford, Texas. Originally incorporated as Norwell, Inc., the company changed its name to Greenwich LifeSciences in March 2018 and went public in September 2020. The company focuses exclusively on developing novel cancer immunotherapies targeting breast cancer and other cancers that express the HER2/neu protein, with its lead product candidate GP2 having completed Phase IIb clinical trials.
Business
Greenwich LifeSciences operates in the biotechnology sector, specifically focusing on cancer immunotherapy development. The company's core mission centers around creating treatments that harness the body's immune system to fight cancer, particularly breast cancer. The company's flagship product is GP2, an immunotherapy designed to prevent breast cancer recurrences in patients who have previously undergone surgery. To understand GP2's significance, it's important to know that many breast cancers express a protein called HER2/neu on their surface. This protein can serve as a target for both existing treatments and the body's immune system. GP2 works by training the patient's immune system to recognize and attack cancer cells that express HER2/neu, potentially preventing cancer from returning after initial treatment. The immunotherapy approach represents a significant advancement in cancer treatment philosophy. Traditional cancer treatments like chemotherapy and radiation work by directly killing cancer cells, often with significant side effects. Immunotherapies like GP2 instead work by educating and empowering the patient's own immune system to recognize cancer cells as foreign invaders and eliminate them naturally. This approach can potentially provide longer-lasting protection with fewer side effects. Greenwich LifeSciences operates as a single-segment company, with 100% of its focus and resources dedicated to developing GP2 and related HER2/neu-targeting immunotherapies for breast cancer and other HER2-expressing cancers.
Revenue model
As a clinical-stage biopharmaceutical company, Greenwich LifeSciences does not yet generate meaningful revenue from product sales. The company's current business model is entirely focused on research and development, funded primarily through equity financing and cash reserves. In 2024, the company reported minimal revenue of $3,612 in Q4, likely from interest or other non-operational sources, while burning approximately $15.8 million in operating expenses for the full year. The company's future revenue model will depend on successfully advancing GP2 through clinical trials and regulatory approval. Once approved, Greenwich LifeSciences would likely generate revenue through direct product sales to hospitals, cancer treatment centers, and oncology practices. The target customers would be healthcare providers treating breast cancer patients, particularly those with HER2-positive tumors who have completed primary treatment and are at risk of recurrence. Several factors could significantly impact the company's future profitability. Positive clinical trial results would dramatically increase the company's value and potential revenue, while negative results could effectively end the business. The competitive landscape in breast cancer treatment is intense, with large pharmaceutical companies like Roche (Herceptin) and others developing competing HER2-targeted therapies. Regulatory approval timelines from the FDA will directly impact when revenue generation can begin. Additionally, the company's ability to secure favorable reimbursement rates from insurance providers will be crucial for commercial success, as cancer immunotherapies can be expensive and require insurance coverage for widespread adoption. The company's current cash burn rate of approximately $7.3 million annually means it must either achieve commercialization or secure additional funding to continue operations beyond its current cash runway.
Competitive moat
Greenwich LifeSciences operates in a highly competitive biotechnology space with limited sustainable competitive advantages at this stage. The company's primary potential moat lies in its intellectual property portfolio surrounding GP2 and its specific approach to HER2/neu immunotherapy. If GP2 proves successful in clinical trials, the company could establish first-mover advantage in this specific therapeutic approach. However, the company's moat is relatively weak compared to established pharmaceutical giants. Large companies like Roche, Pfizer, and others have extensive resources, established relationships with healthcare providers, and multiple approved HER2-targeted therapies already on the market. These companies can invest significantly more in research and development and have the infrastructure to rapidly bring competing products to market. The biotechnology industry is characterized by high regulatory barriers, which can provide some protection once a drug is approved, but also creates significant risk during the development phase. Greenwich LifeSciences faces the constant threat that larger competitors could develop superior therapies or that existing treatments could prove more effective than GP2. The company's small size and single-product focus creates both opportunity and vulnerability. While this allows for focused development efforts, it also means the company has no diversification to fall back on if GP2 fails. Additionally, the company lacks the financial resources to engage in patent litigation or extensive marketing campaigns that larger pharmaceutical companies routinely employ to protect their market position.
Risks & safety
Greenwich LifeSciences presents a high-risk investment profile with limited margin of safety, typical of early-stage biotechnology companies. • Cash position: $4.1 million in cash and short-term investments as of Q4 2024, down from $13.5 million in 2022 • Burn rate: Approximately $7.3 million annual cash burn from operations in 2024 • Debt level: Zero debt, providing some financial flexibility • Runway: Current cash provides less than 12 months of operating runway at current burn rates • Solvency risk: High - company will need additional funding within the next year to continue operations • Valuation metrics: Price-to-book ratio of 57.7x indicates significant premium to tangible assets • Revenue generation: Essentially no revenue, making traditional valuation metrics irrelevant • Market cap: Approximately $129 million market capitalization supported primarily by clinical trial potential • Other considerations: Single-product dependency creates binary risk profile where success or failure of GP2 determines company viability. Current ratio of 2.6x provides short-term liquidity comfort, but rapidly declining cash reserves pose immediate concern.
Recent development
Based on the available financial data, Greenwich LifeSciences has been in a steady operational phase focused on advancing GP2 through clinical development. The company completed its Phase IIb clinical trial for GP2, representing a significant milestone in proving the therapy's efficacy for preventing breast cancer recurrences. The most notable trend over recent years has been the company's accelerating cash burn, with annual operating cash outflows increasing from $6.2 million in 2022 to $7.3 million in 2024. This suggests intensified research and development activities, likely related to advancing GP2 toward potential regulatory submission or preparing for Phase III trials. The company has maintained a debt-free capital structure throughout this period, relying entirely on equity financing and cash reserves to fund operations. However, the cash position has declined significantly from $13.5 million at the end of 2022 to just $4.1 million by Q4 2024, indicating the urgent need for additional funding. Without detailed earnings call transcripts, specific strategic initiatives beyond the core GP2 development program are not clearly evident from the financial data. The company appears to have maintained its focused approach on the single lead product candidate rather than diversifying into multiple therapeutic programs, which is typical for small biotechnology companies with limited resources.
GLSI company profile · for informational purposes only — not investment advice.
Track GLSI with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free